Lilly Opposes Creating MDL For Cymbalta 'Brain Zap' Suits

By Kira Lerner (September 10, 2014, 2:37 PM EDT) -- Eli Lilly & Co. fired back on Tuesday at plaintiffs' attempt to centralize 28 suits in California alleging the drug company misled them about the "brain zaps" and other negative withdrawal effects they would suffer when they stopped taking antidepressant Cymbalta, telling the U.S. Judicial Panel on Multidistrict Litigation the issues are largely individual.

According to Eli Lilly's motion, the plaintiffs' proposal to centralize the lawsuits alleging they suffered "brain zaps" and other debilitating health problems into multidistrict litigation would not be more convenient for the parties because individual issues predominate over common factual ones.

"There is little to be gained...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!